Ascertainment and Verification of End-Stage Renal Disease and End-Stage Liver Disease in the North American AIDS Cohort Collaboration on Research and Design
Table 2
Characteristics of study participants by outcome.
(a) End-stage renal disease
Characteristicsa
Total
Screened positive
Screened negative
Verified ESRD
Randomly selected subcohortb
43 433
Demographics
Median age at enrollment (years, IQR)
39
(33, 46)
42
(33, 49)
39
(33, 46)
41
(35, 48)
39
(33, 45)
Male sex (, %)
34 611
80%
567
69%
34 044
80%
435
70%
1861
77%
Race and ethnicity (, %)
Non-Hispanic Black
14 720
34%
652
79%
14 068
33%
519
84%
996
41%
Non-Hispanic White
18 068
42%
93
11%
17 975
42%
51
8%
963
40%
Hispanic
5252
12%
55
7%
5197
12%
34
5%
183
8%
Other/unknown
5393
12%
22
3%
5371
13%
16
3%
276
11%
HIV transmission risk (, %)c
Men who have sex with men
20 006
46%
201
24%
19 805
46%
156
25%
1078
45%
Injection drug use
6278
14%
188
23%
6090
14%
142
23%
410
17%
Heterosexual contact
10 576
24%
337
41%
10 239
24%
250
40%
715
30%
Other/unknown
6573
15%
96
12%
6477
15%
72
12%
215
9%
Hepatitis B/C coinfection
Hepatitis C infection (, %)
8222
19%
313
38%
7909
19%
238
38%
576
24%
Hepatitis B infection (, %)
3938
9%
96
12%
3842
9%
73
12%
234
10%
(b) End-stage liver disease
Characteristicsa
Total
Screened positive
Screened negative
Verified ESLD
Randomly selected subcohortb
Demographics
Median age at enrollment (years, IQR)
39
(33, 46)
41
(36, 48)
39
(33, 45)
43
(36, 50)
39
(33, 45)
Male sex (, %)
33 024
80%
1596
79%
31 428
80%
548
85%
1880
78%
Race and ethnicity (, %)
Non-Hispanic black
14 107
34%
764
38%
13 343
34%
180
28%
992
41%
Non-Hispanic white
17 216
42%
901
45%
16 315
41%
323
50%
985
41%
Hispanic
4803
12%
207
10%
4596
12%
75
12%
186
8%
Other/unknown
5337
13%
152
8%
5185
13%
66
10%
277
11%
HIVtransmissionrisk (, %)c
Men who have sex with men
20 006
48%
772
38%
19 234
49%
262
41%
1,087
45%
Injection drug use
6087
15%
581
29%
5506
14%
193
30%
411
17%
Heterosexual contact
10 576
26%
503
25%
10 073
26%
123
19%
716
30%
Other/unknown
4794
12%
168
8%
4626
12%
66
10%
226
9%
Hepatitis B/C coinfection
Hepatitis C infection (, %)
8392
20%
1035
51%
7357
19%
375
58%
588
24%
Hepatitis B infection (, %)
3938
9%
345
17%
3593
9%
151
23%
234
10%
aCharacteristics were measured at enrollment into the cohort with the exception of hepatitis C infection; evidence of hepatitis C infection at enrollment or under observation classified an individual as having infection. Hepatitis B infection was defined by a positive hepatitis B surface antigen or detectable hepatitis B DNA result. Hepatitis C infection was defined as a positive hepatitis C antibody or detectable hepatitis C RNA or genotype result.
bThe subcohort is the group of randomly selected individuals from contributing cohorts, all of whom underwent comprehensive medical record review.
cMen who have sex with men who also reported injection drug use were classified as injection drug use risk.
